Recently, the marketing application for a new indication of a pharmaceutical product from Novo Nordisk gained approval from the State Food and Drug Administration, garnering considerable attention. As a multinational pharmaceutical powerhouse, it is customary for Novo Nordisk to seek new indications for its products. However, what distinguishes this occasion? Ultimately, the spotlight falls on a medication known as Ozempic or Wegovy—its renown spans Europe and the United States, so much so that tales of its “miraculous effects” on weight loss have reached the ears of many in China. The principal component of this medication is “semaglutide,” presently approved for diabetes treatment in China. Across Europe and the United States,…